Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 6, 2023
Alectinib - induced acute renal failureElena Prado-Mel, Pablo Ciudad-Gutiérrez, Almudena Sánchez-Martín, et al.Biology|February 25, 2023
Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung CancerRocío Jiménez Galán, Elena Prado-Mel, Maria Alvarez de Sotomayor, et al.Biology|September 28, 2021
Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World PopulationRocío Jiménez Galán, Elena Prado-Mel, María Antonia Pérez-Moreno, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 13, 2024
Efficacy and safety of niraparib in platinum-sensitive recurrent ovarian cancer: retrospective observational study in a tertiary hospitalElena Prado-Mel, Paloma Suárez-Casillas, Lupe Rodríguez-de Francisco, et al.Healthcare (Basel, Switzerland)|June 2, 2021
Association between Anticholinergic Burden and Constipation: A Systematic ReviewHéctor Rodríguez-Ramallo, Nerea Báez-Gutiérrez, Elena Prado-Mel, et al.Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 14, 2025
[Translated article] Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative reviewEva María Legido Perdices, Fernando do Pazo Oubiña, Elena Prado Mel, et al.Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 27, 2025
Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative reviewEva María Legido Perdices, Fernando do Pazo Oubiña, Elena Prado Mel, et al.Archives of Gerontology and Geriatrics|February 16, 2024
Reducing the drug burden of sedative and anticholinergic medications in older adults: a scoping review of explicit decision criteriaHector Rodríguez-Ramallo, Nerea Báez-Gutiérrez, Ángela Villalba-Moreno, et al.Future Oncology (London, England)|September 12, 2024
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety studyIsabel María Carrión-Madroñal, Rocío Díaz-Acedo, Santiago José Lora-Escobar, et al.Journal of Clinical Medicine|January 28, 2026
Impact of UGT1A1*28 Allele on the Safety and Effectiveness of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: Real-World EvidenceFernando do Pazo-Oubiña, Betel Del Rosario García, Marta Miarons, et al.Pageof 1